Abstract
Attempts to address the significant impact of HAART on medical variables on the Malaysian HIV/AIDS population have yet to be evaluated. This study aims to analyze the proportions of AIDS-defining illnesses (ADIs) before and after HAART. A retrospective study was carried out on 128 new cases of HIV infected patients who first commenced HAART in 2004 at the national HIV reference center. Before commencement of HAART, 76 clinical episodes of ADIs were recorded in 52 patients. Most common being pulmonary Mycobacterium tuberculosis (28.9%), PCP (27.6%) and disseminated and extrapulmonary Mycobacterium tuberculosis (11.8%). During HAART, 8 clinical episodes of ADIs were documented in 7 patients with a median time of onset of 10 weeks after initiation of HAART (range, 4-36 weeks). The median CD4 count at the time of the commencement of HAART for these patients was 11 cells/mm3. ADIs reported include PCP (2 episodes), disseminated and extrapulmonary Mycobacterium tuberculosis (2 episodes), extrapulmonary cryptococcosis (1 episode), esophageal candidiasis (1 episode), recurrent pneumonia (1 episode) and disseminated or extrapulmonary histoplasmosis (1 episode). Three (37.5%) of these occurred despite a reduction of viral load by at least 2 log10 and an increased in the CD4 cell count. In conclusion, ADIs can still present after the initiation of successful HAART especially in those with CD4 counts below 100 cells/mm3. In Malaysia, ADIs are the major causes of HIV/AIDS associated morbidity and mortality, thus increased awareness on the management of these illnesses is warranted especially in the months following HAART.
Keywords: AIDS-defining illnesses, HAART, immune restoration diseases, Malaysia
Current HIV Research
Title: AIDS-Defining Illnesses: A Comparison Between Before and After Commencement of Highly Active Antiretroviral Therapy (HAART)
Volume: 5 Issue: 5
Author(s): Yvonne Lim Ai Lian, Benedict Sim Lim Heng, Veeranoot Nissapatorn and Christopher Lee
Affiliation:
Keywords: AIDS-defining illnesses, HAART, immune restoration diseases, Malaysia
Abstract: Attempts to address the significant impact of HAART on medical variables on the Malaysian HIV/AIDS population have yet to be evaluated. This study aims to analyze the proportions of AIDS-defining illnesses (ADIs) before and after HAART. A retrospective study was carried out on 128 new cases of HIV infected patients who first commenced HAART in 2004 at the national HIV reference center. Before commencement of HAART, 76 clinical episodes of ADIs were recorded in 52 patients. Most common being pulmonary Mycobacterium tuberculosis (28.9%), PCP (27.6%) and disseminated and extrapulmonary Mycobacterium tuberculosis (11.8%). During HAART, 8 clinical episodes of ADIs were documented in 7 patients with a median time of onset of 10 weeks after initiation of HAART (range, 4-36 weeks). The median CD4 count at the time of the commencement of HAART for these patients was 11 cells/mm3. ADIs reported include PCP (2 episodes), disseminated and extrapulmonary Mycobacterium tuberculosis (2 episodes), extrapulmonary cryptococcosis (1 episode), esophageal candidiasis (1 episode), recurrent pneumonia (1 episode) and disseminated or extrapulmonary histoplasmosis (1 episode). Three (37.5%) of these occurred despite a reduction of viral load by at least 2 log10 and an increased in the CD4 cell count. In conclusion, ADIs can still present after the initiation of successful HAART especially in those with CD4 counts below 100 cells/mm3. In Malaysia, ADIs are the major causes of HIV/AIDS associated morbidity and mortality, thus increased awareness on the management of these illnesses is warranted especially in the months following HAART.
Export Options
About this article
Cite this article as:
Ai Lian Yvonne Lim, Lim Heng Benedict Sim, Nissapatorn Veeranoot and Lee Christopher, AIDS-Defining Illnesses: A Comparison Between Before and After Commencement of Highly Active Antiretroviral Therapy (HAART), Current HIV Research 2007; 5 (5) . https://dx.doi.org/10.2174/157016207781662425
DOI https://dx.doi.org/10.2174/157016207781662425 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV vaccine development
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
Lymphomas in people living with HIV (PLWH)
In the era of combined antiretroviral therapy (cART), the incidence of lymphoma among people living with HIV (PLWH) surpassed Kaposi's sarcoma in 2011, becoming the most common AIDS-defining malignancy. The annual incidence rate ranges approximately from 100 to 300 per 100,000 individuals with HIV infection as the population denominator, which ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advancement in Predicting Subcellular Localization of Mycobacterial Protein with Machine Learning Methods
Medicinal Chemistry Synthesis and Antitubercular Activity of a Series of Thiazole Derivatives
Anti-Infective Agents Discovering and Developing New Medicines for Malaria Control and Elimination
Infectious Disorders - Drug Targets Recent Progress in Small Molecular Inhibitors of DNA Gyrase
Current Medicinal Chemistry Monoclonal Antibodies Carried in Drug Delivery Nanosystems as a Strategy for Cancer Treatment
Current Medicinal Chemistry Medicinal Chemistry of Inhibitors Targeting Resistant Bacteria
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: The Lab-on-a-protein Concept Protein as Powerful Nanometric Laboratory for Chemical Sciences)
Current Organic Chemistry In-vitro Antioxidant activity of ‘Aswathy Chooranam’- a Siddha Drug
Current Traditional Medicine Role of Cytokines in Chlamydia trachomatis Protective Immunity and Immunopathology
Current Pharmaceutical Design Investigation of the Antimycobacterial Activity of 8-hydroxyquinolones
Medicinal Chemistry The IL23/Th17 Pathway as a Therapeutic Target in Chronic Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Natural Aristolochia Alkaloid Aristololactam-β-D-glucoside: Interaction with Biomacromolecules and Correlation to the Biological Perspectives
Mini-Reviews in Medicinal Chemistry The Role of Coagulation and Fibrinolysis in the Pathogenesis of Acute Lung Injury
Current Respiratory Medicine Reviews Drug Delivery for Ocular Allergy: Current Formulation Design Strategies and Future Perspectives
Current Pharmaceutical Design Thiazole-based Chalcone Derivatives as Potential Anti-inflammatory Agents: Biological Evaluation and Molecular Modelling
Current Topics in Medicinal Chemistry Intracellular Drug Delivery: Mechanisms for Cell Entry
Current Pharmaceutical Design Despite an Extensive Sequence Analysis Identification of Functional Candidates Amongst Hypothetical Proteins of Neisseria gonorrhoeae
Letters in Drug Design & Discovery Chronic Stress and Diabetes Mellitus: Interwoven Pathologies
Current Diabetes Reviews Clinical Management of Drug-resistant Mycobacterium tuberculosis Strains: Pathogen-targeted Versus Host-directed Treatment Approaches
Current Pharmaceutical Biotechnology Modified and Mutant Porins in the Study on Molecular Basis of Non- Specific Diffusion
Current Protein & Peptide Science